title: Gender-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation.
abstract: Several studies have found that among patients with ST-elevation myocardial infarction (STEMI) treated by thrombolysis, female sex is associated with a worse outcome. The aim of this study was to investigate sex-related differences in clinical and angiographic findings in patients with STEMI treated with primary angioplasty and Gp IIb-IIIa inhibitors. Our population is represented by 1662 patients undergoing primary angioplasty included in the EGYPT database. Myocardial perfusion was evaluated by myocardial blush grade and ST-segment resolution. Follow-up data were collected between 30 days and 1 year after primary angioplasty. Among 1662 patients, 379 were women (22.8%). Female sex was associated with more advanced age, higher prevalence of diabetes, hypertension, more advanced Killip class, longer ischemia time, less often smokers, with higher prevalence of preprocedural recenalization. No difference was observed in terms of postprocedural TIMI flow, myocardial perfusion and distal embolization. Similar findings were observed in terms of enzymatic infarct size and preprocedural ejection fraction. Female gender was associated with higher mortality (6.4% vs. 3.6%, HR = 1.83 [1.12-3.0], P = 0.015). However, the difference disappeared after correction for baseline confounding factors (HR = 1.01 [0.56-1.83], P = 0.98). This study shows that in patients with STEMI treated by primary angioplasty, female gender is associated with higher mortality rate in comparison with men, and this is mainly due to their higher clinical and angiographic risk profiles. In fact, female sex did not emerge as an independent predictor of mortality.
authors.affiliation: Division of Cardiology, Maggiore della Carità Hospital, Eastern Piedmont University, Novara, Italy. giuseppe.deluca@maggioreosp.novara.it
authors.forename: Giuseppe
authors.initials: G
authors.lastname: De Luca
authors.forename: C Michael
authors.initials: CM
authors.lastname: Gibson
authors.forename: Mariann
authors.initials: M
authors.lastname: Gyöngyösi
authors.forename: Uwe
authors.initials: U
authors.lastname: Zeymer
authors.forename: Dariusz
authors.initials: D
authors.lastname: Dudek
authors.forename: Hans-Richard
authors.initials: HR
authors.lastname: Arntz
authors.forename: Francesco
authors.initials: F
authors.lastname: Bellandi
authors.forename: Mauro
authors.initials: M
authors.lastname: Maioli
authors.forename: Marko
authors.initials: M
authors.lastname: Noc
authors.forename: Simona
authors.initials: S
authors.lastname: Zorman
authors.forename: H Mesquita
authors.initials: HM
authors.lastname: Gabriel
authors.forename: Ayse
authors.initials: A
authors.lastname: Emre
authors.forename: Donald
authors.initials: D
authors.lastname: Cutlip
authors.forename: Tomasz
authors.initials: T
authors.lastname: Rakowski
authors.forename: Kurt
authors.initials: K
authors.lastname: Huber
authors.forename: Arnoud W J
authors.initials: AW
authors.lastname: van't Hof
mesh_terms: D000368:Aged; D017130:Angioplasty / Q000009:adverse effects / Q000401:mortality; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009026:Mortality; D009203:Myocardial Infarction / Q000150:complications / Q000453:epidemiology* / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D012307:Risk Factors; D012737:Sex Factors; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex